This recently established 1-year residency, authorized by ASHP, will increase the number of expert clinicians equipped to effectively manage patients at risk for thrombosis and bleeding, and support the creation of anticoagulation stewardship programs nationwide.
The award payment offers each institution $120,000 over a 2-year period. The goal of this grant is to support the institution in developing the new program, as well as provide salary assistance for two consecutive residency years.
The AC Forum will award up four 2-year grants in 2022 and 4 additional 2-year grants in 2023.
The application for the 2023-24 award cycle will open by August 22, 2022 and will be due by September 10, 2022. Sites will be notified by September 20 if they are selected.
The Brigham and Women’s Hospital in Boston Massachusetts, with support from the Anticoagulation Forum and ASHP, launched the nation's first PGY2 Residency in Thrombosis and Hemostasis Management in July 2022. This novel specialty residency program was formally approved by the ASHP Council on Credentialing (COC) in April 2022. The necessary framework on goals, objectives and structure have been finalized and will be posted in PharmAcademic in Fall 2022 for programs interested in accessing this information.
Applicants must be US-based organizations with existing ASHP-accredited pharmacy residency programs and advanced pharmacy practices in the prevention and treatment of thrombosis and bleeding.
The Residency Program Director (RPD) must have either 1) completed a PGY2 residency in a related specialty area and have 3+ years of practice experience OR 2) have 5 years of practice experience in a relevant specialty area. The RPD should also be board certified in either Pharmacotherapy, Ambulatory Care, or Cardiology or have obtained recognition as a Certified Anticoagulation Care Provider from the National Certification Board for Anticoagulation Providers. The Director must also actively practice in a clinical area involving anticoagulation management.
Each awarded residency program will select the PGY2 resident via their own selection process, using their own criteria such as clinical excellence, academic potential, leadership ability, teaching skills, and demonstrated interest in thrombosis and hemostasis-related care. The AC Forum recommends that diversity, equity, and inclusion be prioritized as part of the selection process at each institution.
An online portal for applications for the 2023-24 TRAIN Pharmacy Grant will open by August 22, 2022 and are due on September 10, 2022.
Sites will be asked to provide the following in the application:
Institutions will be selected by an Anticoagulation Forum Review Committee based on their ability to train well-rounded residents, clinical and research expertise in relevant areas, and the program’s focus on thrombosis and hemostasis management. Reviewers with a conflict of interest will be recused from reviewing the specific application. Selected institutions will be notified of grant awards by September 20, 2022 and will be required to sign a Grant Agreement with the Anticoagulation Forum.
Questions the Review Committee will consider include:
Sites awarded funding will be expected to also pursue ASHP accreditation for their residency program, including the submission of precandidate application to ASHP by September 30, 2022 for the 2022 TRAIN grant cycle.
A summary of key accreditation milestones and timelines are available here.
Official resources for ASHP accreditation are available here.
The PGY2 Residency in Thrombosis and Hemostasis Management will provide advanced training devoted to the prevention, treatment, and clinical and operational management of thrombosis and bleeding. While the resident will complete a research project, the focus of the program is clinical practice and the development of skills in health system operations and improvement.
Residents will complete experiences and develop skills and competencies that prepare them to take active and productive roles in system-level anticoagulation stewardship programs. The required and elective experiences will include such activities as:
Through participation in this one-year residency program in thrombosis and hemostasis care, PGY2 residents will:
Residents, along with their RPDs, will be expected to participate in a bi-weekly virtual seminar series moderated by faculty from each of the AC Forum PGY2 Residency sites. Seminars will focus on key subject matter topics within the thrombosis and hemostasis curriculum, as well as those related to career development. Residents will also have the opportunity to present complex cases to senior panelists.
RPDs and their faculty will work collaboratively to develop the content and syllabus for the seminar series, with support from the Anticoagulation Forum.
Anticoagulants are the leading class of medications associated with emergency department visits for adverse events. The rapid expansion of approved anticoagulants, indications for their use, associated reversal strategies, and increasing overall prescribing makes safe and effective patient care increasingly complex and costly. Pharmacists play pivotal roles in thrombosis and hemostasis management and in the implementation and operation of successful multidisciplinary anticoagulation and hemostasis stewardship programs. Yet currently available residency programs do not fully prepare pharmacists for work in this dynamic and expanding field. This new ASHP-accredited PGY2 Residency in Thrombosis and Hemostasis Management will prepare pharmacists to practice in this rapidly evolving discipline and to cement the role of pharmacists in multidisciplinary anticoagulation stewardship programs.
The Anticoagulation Forum (AC Forum) is a nonprofit organization dedicated to improving the quality of patient care by educating healthcare professionals and advocating for clinical best practices in the field of antithrombotic medications. Founded in 1991, the AC Forum is the largest organization of anticoagulation management specialists, made up of 14,000 physicians, pharmacists, and nurses representing over 3,000 anticoagulation practices and supporting over 1 million patients annually.
Institutions must be able to accept grant funding that may be subject to Sunshine Act reporting. The Anticoagulation Forum may be required to report information on the Residency award institution, Residency Program Director, resident, or other details of the program to AstraZeneca and the BMS/Pfizer Alliance to comply with the Sunshine Act.
Funding for the TRAIN Pharmacy Grant is provided by AstraZeneca and the BMS/Pfizer Alliance.
Questions? Contact the Anticoagulation Forum at firstname.lastname@example.org.